Hypoglycemia - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for hypoglycemia including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentation such as therapy, route of administration, target, and mechanism of action.

Overview of the drug development pipeline for hypoglycemia

It has been observed that abnormally low blood sugar level is one of the major causes of hypoglycemia and is characterized by a condition in which the glucose level in the blood falls below the normal levels. According to the National Center for Chronic Disease Prevention and Health Promotion, the estimated number of emergency department visits in the US with hypoglycemia as the first-listed diagnosis and diabetes as the second-listed disease was a stable figure. The common symptoms of hypoglycemia are the weakness in the individual accompanied by dizziness and confusion and the condition is related to the treatment of diabetes. The severity of hypoglycemia may vary from one person to another, and it can develop in both children and adults, especially those with diabetes. The most efficient approach for the treatment of hypoglycemia is forecasted to be monotherapy.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for hypoglycemia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Want a bigger picture? Try a FREE sample of this report now!

Pipeline analysis report on drug development for hypoglycemia: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hypoglycemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• ADOCIA
• Arecor
• Eiger BioPharmaceuticals
• Eli Lilly
• Heptares Therapeutics

Therapeutic assessment of the drug development pipeline for hypoglycemia by route of administration

• Subcutaneous
• Parenteral
• Intravenous
• Oral
• Intranasal

The subcutaneous route of administration (ROA) involves the delivery of the drug directly into the layer of the skin below the dermis and epidermis and in the parenteral technique, the drug molecules are administered elsewhere in the body other than the mouth and alimentary canal. Intravenous route of administration involves delivery of the drug molecules through veins while the oral method is done by delivering the drug directly into the mouth cavity. Intranasal is another technique where the drug molecules are administered through the nasal structure.

Therapeutic assessment of the drug development pipeline for hypoglycemia by therapy

• Monotherapy

According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for hypoglycemia are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug therapy molecules in the various development stages for hypoglycemia?
• What are the companies that are currently involved in the development of drug molecules for hypoglycemia?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.